Suppr超能文献

口服 ω-3 PUFAs 在临时回肠造口术患者远端小肠中的腔室生物利用度,以及对回肠微生物组的相关影响。

Luminal Bioavailability of Orally Administered ω-3 PUFAs in the Distal Small Intestine, and Associated Changes to the Ileal Microbiome, in Humans with a Temporary Ileostomy.

机构信息

Leeds Institute of Medical Research, St James's University Hospital, University of Leeds, Leeds, United Kingdom.

Department of Hepatobiliary Surgery, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

出版信息

J Nutr. 2021 Aug 7;151(8):2142-2152. doi: 10.1093/jn/nxab113.

Abstract

BACKGROUND

Oral administration of purified omega-3 (ω-3) PUFAs is associated with changes to the fecal microbiome. However, it is not known whether this effect is associated with increased PUFA concentrations in the gut.

OBJECTIVES

We investigated the luminal bioavailability of oral ω-3 PUFAs (daily dose 1 g EPA and 1g DHA free fatty acid equivalents as triglycerides in soft-gel capsules, twice daily) and changes to the gut microbiome, in the ileum.

METHODS

Ileostomy fluid (IF) and blood were obtained at baseline, after first capsule dosing (median 2 h), and at a similar time after final dosing on day 28, in 11 individuals (median age 63 y) with a temporary ileostomy. Fatty acids were measured by LC-tandem MS. The ileal microbiome was characterized by 16S rRNA PCR and Illumina sequencing.

RESULTS

There was a mean 6.0 ± 9.8-fold and 6.6 ± 9.6-fold increase in ileal EPA and DHA concentrations (primary outcome), respectively, at 28 d, which was associated with increased RBC ω-3 PUFA content (P ≤ 0.05). The first oral dose did not increase the ileal ω-3 PUFA concentration except in 4 individuals, who displayed high luminal EPA and DHA concentrations, which reduced to concentrations similar to the overall study population at day 28, suggesting physiological adaptation. Bacteroides, Clostridium, and Streptococcus were abundant bacterial genera in the ileum. Ileal microbiome variability over time and between individuals was large, with no consistent change associated with acute ω-3 PUFA dosing. However, high concentrations of EPA and DHA in IF on day 28 were associated with higher abundance of Bacteroides (r2 > 0.86, P < 0.05) and reduced abundance of other genera, including Actinomyces (r2 > 0.94, P < 0.05).

CONCLUSIONS

Oral administration of ω-3 PUFAs leads to increased luminal ω-3 PUFA concentrations and changes to the microbiome, in the ileum of individuals with a temporary ileostomy. This study is registered on the ISRCTN registry as ISRCTN14530452.

摘要

背景

口服纯化的ω-3(ω-3)多不饱和脂肪酸(PUFAs)与粪便微生物群的变化有关。然而,尚不清楚这种影响是否与肠道中 PUFAs 浓度的增加有关。

目的

我们研究了口服 ω-3 PUFAs(每日剂量 1 g EPA 和 1 g DHA 游离脂肪酸当量作为软凝胶胶囊中的甘油三酯,每日两次)在回肠中的腔内生物利用度和肠道微生物组的变化。

方法

在 11 名临时回肠造口术患者中,在基线时、首次胶囊给药后(中位数 2 小时)以及第 28 天最后一次给药后相似时间,获得回肠造口液(IF)和血液。通过 LC-串联 MS 测量脂肪酸。通过 16S rRNA PCR 和 Illumina 测序来描述回肠微生物组。

结果

在 28 天时,EPA 和 DHA 浓度分别平均增加了 6.0±9.8 倍和 6.6±9.6 倍(主要结局),这与 RBC ω-3 PUFA 含量增加有关(P≤0.05)。首次口服剂量并未增加回肠 ω-3 PUFA 浓度,除 4 名个体外,这些个体显示出高腔 EPA 和 DHA 浓度,这些浓度在第 28 天降低至与整个研究人群相似的浓度,表明存在生理适应。拟杆菌属、梭菌属和链球菌属是回肠中丰富的细菌属。回肠微生物组随时间和个体的变化很大,与急性 ω-3 PUFA 给药无一致变化相关。然而,IF 中 EPA 和 DHA 的高浓度在第 28 天与拟杆菌属的丰度增加相关(r2>0.86,P<0.05),与其他属的丰度降低相关,包括放线菌属(r2>0.94,P<0.05)。

结论

口服 ω-3 PUFAs 可导致临时回肠造口术患者的回肠腔内 ω-3 PUFAs 浓度增加和微生物组的变化。这项研究在 ISRCTN 注册处注册为 ISRCTN84352322。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b12/8349127/4d4b08e40300/nxab113fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验